Episode: 46 - Leveraging Albumin and IgG FcRn-Mediated Regulation in Therapeutic Development

The Chain: Protein Engineering Podcast

Contenuto fornito da Cambridge Healthtech Institute. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Cambridge Healthtech Institute o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

1+ y ago 36:20

MP3•Pagina principale dell'episodio

Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sits down with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to discuss the unique properties of FcRn and how it can be leveraged for novel therapeutic development. Additionally, Andersen details the mechanics of FcRn binding, why it prolongs albumin and IgG half-lives, and notable FcRn technological advancements and research findings in animal and human models. He also talks about engineering blood proteins for optimal function and launching his new venture, Authera, the preclinical stage biotech company using an FcRn-centered platform to study the receptor’s versatility across multiple cell types.
Links from this episode:
University of Oslo
Mythic Therapeutics
Authera

65 episodi

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors